• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Advanced Cell Technology

edit

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. It primarily focuses on cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company’s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. is also generating stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company’s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Worcester, Massachusetts.

Recent Milestones

edit

• 
  Advanced Cell Technology — has landed a $25 million financing and been cleared by the U.S. Food and Drug Administration for its Investigational New Drug application (1/3/11)
  Posted 1/4/11 at 4:07am via masshightech.com
• 
  Advanced Cell Technology received $25M in Venture Round funding. (1/2/11)
  Posted 1/3/11 at 9:26pm via advancedcell.com
• 
  Advanced Cell Technology — William M. Caldwell IV, chairman and CEO of Advanced Cell Technology Inc. of Marlborough, died Monday evening unexpectedly. (12/14/10)
  Posted 12/15/10 at 5:31am via masshightech.com
• 
  Advanced Cell Technology — has filed an Investigational New Drug application with the U.S. Food and Drug Administration for its treatment of Dry Age-Related Macular Degeneration (Dry AMD). (11/30/10)
  Posted 12/1/10 at 5:32am via masshightech.com
• 
  Advanced Cell Technology — Advanced Cell Technology Inc. has completed Phase 1 human clinical trials of its myoblast program to treat heart failure. (9/29/10)
  Posted 9/29/10 at 9:30am via masshightech.com
• 
  Advanced Cell Technology — Won 2 patents related to its stem cell-derived regenerative technology used to treat eye disorders (9/14/10)
  Posted 9/15/10 at 3:21am via masshightech.com
• 
  Advanced Cell Technology received $2.78M in Debt funding. (11/12/09)
  Posted 12/7/09 at 12:00pm via sec.gov
• 
  Advanced Cell Technology added Robert Lanza as Chief Scientific Officer. (1/1/99)
  Posted 9/28/10 at 1:30am
• 
  Advanced Cell Technology added Gary Rabin as Chairman and CEO.
  Posted 8/19/11 at 6:10pm
• 
  Advanced Cell Technology added Michael T. Heffernan as Board of Directors.
  Posted 4/9/12 at 7:23pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 3/29/10

Sources

1. SEC (sec.gov) [edit]
2. Advanced Cell Technology Secures $25 Million Funding Commitment (advancedcell.com) [edit]
ACT lands patents for stem cell-derived eye treatment (masshightech.com) [edit]
Mass High Tech (masshightech.com) [edit]
ACT seeks human trials of its stem cell-linked eye treatment (masshightech.com) [edit]
ACT chairman, CEO Caldwell dies (masshightech.com) [edit]
ACT's Dry AMD therapy boosted by $25M funding, FDA clearance (masshightech.com) [edit]